Articles related to Hematology/Oncology

This is the third edition of the guidelines – the last coming in 2014 – providing a resource and guidance specifically for primary care practitioners about how to plan care for childhood cancer survivors. “A care plan just really encourages coordination, especially if a child has a very complicated post-cancer treatment history with a lot of morbidity,” said Dr. Melissa Hudson, director of the division of cancer survivorship at St. Jude’s and corresponding author of the new guidelines.

About 75% to 80% of children with pediatric AML have clonal, acquired, somatic cytogenetic abnormalities (CAs) detected. Hematology Advisor briefs the information originally appearing in Genes, which reviews the current knowledge on evaluating pediatric patients based on cytogenetics and molecular subtypes to help match patients to risk-adapted therapies.

Publication: Blood AdvancesStudy Design: Prospective study with unmatched health care workforce control group, receiving either Moderna or Pfizer COVID vaccination.Study Population: 23 patients with CLL (61%), lymphoma (39%) (including DLBCL), MCL (13%) and 4% with less common lymphomas.Outcome: Lymphoma patients had significantly lower anti-S IgG titers 28 days post-vaccination compared with controls. Related Article: Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with B-Cell Non-Hodgkin Lymphoma

An oncologist pens an essay about his 10-year-old son who died in March 2021 from diffuse midline glioma, providing a glimpse into his own extreme truths about the burden he carries in treating cancer patients.

Publication: JAMA OncologyMethod: Retrospective study of 160 adults with hematologic malignant disease who were vaccinated with 1 of 3 COVID-19 vaccines (February through April 2021).Results: Patients receiving B-cell-depleting immunotherapy may not gain adequate protection from vaccination and may still develop a potentially fatal infection.

Source: Blood AdvancesKey Points: In a cohort of 154 patients with NHL or MM receiving CAR T-cells, clonal hematopoiesis of indeterminate potential (CHIP) was present in 48%. Although associated with worse prognosis in these patients receiving autologous transplantation, no such association was seen in these patients receiving CAR T. Instead, the authors saw increased rates of complete response and cytokine release syndrome severity in the younger than 60 population. However, there was no difference in progression-free or overall survival, regardless of age. Design: Cohort review of 154 patients with NHL or MM receiving CAR T-cells